Sign in
Taking people in South AfricaNo phase

Two-probe heat treatment for cervical precancer in women with HIV

Tests heat treatment with one or two probes for cervical precancer in women with HIV.

Key facts

Who runs it
Fred Hutchinson Cancer Center
Where
Durban, South AfricaSee the site
Trial code
Registry title
Feasibility Study Comparing One vs Two Probes for Thermal Ablation Among Cervical Cancer Screen Positive WLWH in C1001P-CS9 South Africa
Status
Recruiting
People taking part
200 people, planned
Started
15 Oct 2026
Expected to end
31 May 2028
Type of study
Interventional, 2 groups
Treatments tested
  • Thermal ablation (TA) with 1 probe
  • Thermal ablation (TA) with 2 probes
Record updated
3 November 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for women aged 25 to 49 who live with HIV and have a positive cervical screening test. It compares treating cervical precancer with one heat probe or two.

Age
25 to 49 years
Sex
Women only
Disease stage
Positive hrHPV or VIA screening test within 3 months of joining; Type 1 transformation zone (TZ1); able to have thermal ablation
Earlier treatment
Must not have had treatment for cervical precancer before
Biomarker or test result
Positive hrHPV or VIA test within 3 months of joining

Main reasons for not taking part

  • Screened for cervical cancer outside the study in the last 6 months
  • Pregnant now or less than 6 weeks after giving birth
  • Earlier diagnosis of cervical cancer
  • Total hysterectomy
  • Currently being treated for any cancer

This trial only enrols participants living with HIV. The registry sentence this rests on: Living with HIV

The registry criteria, word for word

Show all 16 criteriaShow less

Who can take part

  • 25-49 years old
  • Living with HIV
  • Intact cervix
  • Willing to return to facility at 6 months
  • Willing and able to provide informed consent
  • Positive hrHPV or VIA test within 3 months of enrollment
  • Type 1 transformation zone (TZ1)
  • Thermal ablation eligible

Who cannot take part

  • Prior diagnosis of cervical cancer
  • Currently receiving treatment for any cancer
  • Screened for cervical cancer outside of study in last 6 months
  • A history of treatment for cervical precancer
  • Individual has a condition that the Clinical Site PI believes will interfere with or affect the conduct, results, or completion of the clinical study
  • Individual has a condition that the Clinical Site PI considers creates an unacceptable risk to the individual if enrolled
  • Currently pregnant or less than 6 weeks postpartum
  • Total hysterectomy

The main criteria, as questions

These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Are you between 25 and 49 years old?

This trial is currently available in South Africa.

  • Centre for the AIDS Programme of Research in South AfricaDurban, South AfricaContact: Nivashnee Naicker, MBChB, MAS, MPHTaking people

About the trial

What the trial wants to find out

Cervical cancer disproportionately affects women in low- and middle-income countries (LMICs), particularly women living with HIV (WLWH) who have a 6-fold increased risk of cervical cancer compared to women in the general population. Thermal ablation (TA) is recommended by the World Health Organization (WHO) to treat cervical precancerous lesions, although its efficacy can be suboptimal in WLWH. The proposed study will evaluate the feasibility, acceptability, and safety of a two-probe TA technique (endocervical and ectocervical probes) and whether this approach improves treatment outcomes among WLWH compared to one (ectocervical) probe. This innovation has the potential to significantly enhance cervical cancer prevention efforts in high-burden settings. It will also contribute towards achieving the 90-70-90 goals of the WHO strategy for accelerated elimination of cervical cancer as a public health problem by 2030.

The 2 groups in the trial

  • Group 1 (TA with 1 probe)Treatment being tested

    Participants undergo a clinical exam, soft-brush endocervical and ectocervical biopsies, digital imaging, and visual assessment for TA, and if eligible undergo TA with 1 probe at month 0.

    Treatment: Thermal ablation (TA) with 1 probe

  • Group 2 (TA with 2 probes)Treatment being tested

    Participants undergo a clinical exam, soft-brush endocervical and ectocervical biopsies, digital imaging, and visual assessment for TA, and if eligible undergo TA with 2 probes at month 0.

    Treatment: Thermal ablation (TA) with 2 probes

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Expanded Use of Thermal Ablation (EXCEL Cohort) and Prophylactic Use of Two Probes (PRO Cohort) for Cervical Cancer Prevention in Women Living With HIV
Plain-language title
Two-probe heat treatment for cervical precancer in women with HIVGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 13 November 2026.
Criteria questions
Built from NCT07645378, who can take part
Record updated
3 November 2026